CDK1参与肝细胞癌的发展机制及其抑制剂应用价值  

Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value

作　　者：叶凯丽 郑雯 叶啟发[1] 杨岚[1,2] YE Kaili;ZHENG Wen;YE Qifa;YANG Lan(Zhongnan Hospital of Wuhan University,Liver Disease Research Institute,Wuhan University,Wuhan University Medical Center,Transplantation of Hubei Province Key Laboratory of Medical Technology,Wuhan 430071,Hubei,China;The Third Xiangya Hospital of Central South University,Engineering Research Center of Transplantation Medicine,Ministry of Health,Third Xiangya Hospital,Central South University,Changsha 410013,Hunan,China)

机构地区：[1]武汉大学中南医院,武汉大学肝胆疾病研究院,武汉大学移植医学中心,移植医学技术湖北省重点实验室,湖北武汉430071 [2]中南大学湘雅三医院,卫生部移植医学工程技术研究中心,湖南长沙410013

出　　处：《中国临床药理学与治疗学》2021年第9期1086-1094,共9页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：医学腾飞计划-“转化医学、医学+医学平台建设项目”(临床医学)(TFLC2018003)。

摘　　要：细胞周期蛋白依赖性激酶1(cyclin-dependent protein kinase 1,CDK1)是一种高度保守的丝氨酸/苏氨酸激酶,在有丝分裂中发挥检查点作用,协调和推动细胞周期进程。肝细胞癌(hepatocellular carcinoma,HCC)中CDK1显著上调,主要与p53信号转导途径、LINC00346-miR-199a-3p-CDK1/CyclinB途径、SNHG16/let-7b-5p/CDC25B/CDK1途径和Upf1-SNORD52-CDK1途径等信号通路相关。本文系统阐述CDK1参与肝癌发生发展的作用机制,阐明CDK1抑制剂靶向治疗HCC现况,可为以CDK1为靶点的HCC治疗提供线索与依据。Cyclin-dependent kinase 1 is a highly conserved serine/threonine kinase that acts as a checkpoint during mitosis,coordinating and promoting cell cycle progression.CDK1 is significantly upregulated in hepatocellular carcinoma.It is mainly related to p53 signal transduction pathway,LINC00346-miR-199 a-3 p-CDK1/CyclinB pathway,SNHG16/let-7 b-5 P/CDC25 B/CDK1 pathway and UPF1-SNord52-CDK1 pathway.In this paper,the mechanism of CDK1 involvement in the occurrence and development of hepatocellular carcinoma was systematically elaborated,and the current situation of CDK1 inhibitor targeted treatment of HCC was clarified,which could provide clues and basis for the treatment of HCC with CDK1 as the target.

关 键 词：细胞周期蛋白依赖性激酶1 细胞周期蛋白 肝细胞癌 细胞周期 

分 类 号：R979.1[医药卫生—药品] Q279[医药卫生—药学]